Eidos Therapeutics Status
The company raised $106.25 million in its initial public offering on the Nasdaq Stock Exchange under the ticker symbol of EIDX on June 21, 2018. A total of 6,250,000 shares were sold at a price of $17 per share. After the offering, there was a total of 35,814,527 outstanding shares (excluding the over-allotment option) priced at $17 per share, valuing the company at $608.84 million. The underwriters exercised their option to purchase up to an additional 937,500 shares from the company to cover over-allotments, if any. The aggregate gross proceeds to Eidos from the offering were approximately $122.2 million, before deducting underwriting discounts and other offering expenses.